Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 12, 2026

Applied Materials AMAT Q1 2026 Earnings Transcript

View original at nasdaq.com
Applied Materials AMAT Q1 2026 Earnings Transcript Image source: The Motley Fool. Date Thursday, February 12, 2026 at 4:30 p.m…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Gross margin will reflect product and customer mix, as well as continued improvements in productivity and cost, expected to trend favorably as mix normalizes and cost actions take hold

    80% confidence
  • Company has seen some timing shifts typical for the industry, but no material cancellations; overall demand signals remain constructive

    80% confidence
  • Company has made progress diversifying suppliers, increasing dual-sourcing, and localizing critical components

    80% confidence
  • Company is focused on operational discipline and supply chain execution to meet customer demand while advancing technology leadership

    80% confidence
  • In Q1 2026, Applied Materials delivered strong revenue, margins, and cash flow

    80% confidence
  • EUV scaling increases requirements for patterning adjacencies, hard mask engineering, clean, and metrology/inspection

    80% confidence
  • Near term, OpEx will grow modestly, below the pace of revenue, to drive operating leverage while prioritizing R&D and customer support

    80% confidence
  • OpEx will grow at a measured pace focused on R&D and customer enablement, with discipline on overhead

    80% confidence
  • Customers continue to accelerate node migrations and new 3D scaling approaches, expanding opportunity for differentiated materials engineering portfolio

    80% confidence
  • Company continues to expand capacity in critical product lines and investing in supply resiliency, with lead times improving

    80% confidence
  • Gate-all-around and backside power introduce new materials and integration challenges where company's leadership in materials engineering is a key differentiator

    80% confidence
  • Company closely monitors regulatory developments, including CFIUS-related matters; outlook reflects current regulatory environment with appropriate assumptions incorporated

    80% confidence
  • Services margins are stable to improving, supported by higher attachment, software content, and productivity initiatives

    80% confidence
  • Metrology and inspection are growing as process complexity increases, with e-beam and optical platforms gaining traction

    80% confidence
  • Applied Materials delivered solid results in Q1 2026, driven by strong demand across AI, foundry-logic, and memory

    80% confidence
  • DRAM WFE is leading the recovery, particularly with HBM-driven investments, while NAND is improving at a slower pace

    80% confidence
  • Company is seeing strong pull for tools supporting HBM, including patterning, dielectric deposition, and advanced packaging steps like hybrid bonding and TSV-related processes

    80% confidence
  • ICAPS demand remains healthy, supporting power, automotive, and industrial applications, though growth is moderating from peak levels

    80% confidence
  • Services mix continues to shift toward performance-based contracts

    80% confidence
  • Applied Materials returned capital to shareholders through repurchases and dividends, and continues to invest in R&D and capacity to support long-term growth

    80% confidence
  • Foundry-logic remains healthy with strength at leading nodes, while memory is improving, led by DRAM and HBM-related investments

    80% confidence
  • Both DRAM and NAND segments expected to grow through the year, with DRAM outpacing NAND near term

    80% confidence
  • Capital allocation priorities remain: invest in business for long-term growth, maintain strong balance sheet, and return excess cash through buybacks and dividends

    80% confidence
  • AI demand remains robust and broad-based, supporting sustained WFE strength with continued investment in leading-edge foundry-logic and advanced packaging

    80% confidence
  • Pipeline and customer engagements give confidence in demand durability over the coming quarters

    80% confidence
  • Services growth is supported by expanding installed base, higher attachment to performance-based agreements, and analytics-driven optimization

    80% confidence
  • Applied Materials differentiates with a comprehensive toolset across wafer-level packaging, hybrid bonding, and inspection/metrology

    80% confidence
  • Global footprint and broad portfolio allow supporting customers across regions within the regulatory framework

    80% confidence
  • Company is investing in automation and remote capabilities to enhance uptime and yield for customers

    80% confidence
  • Company expects to continue repurchasing shares at a steady pace while funding strategic investments

    80% confidence

Data points we hold from this source

Applied Materials, Inc. · book to bill ratio1.0 ratio
Applied Materials, Inc. · backlogelevated qualitative
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Applied Materials AMAT Q1 2026 Earnings Transcript — Source | Via News | Finance Via News